ICOS/CD28 antagonist - Alpine Immune Sciences

Drug Profile

ICOS/CD28 antagonist - Alpine Immune Sciences

Alternative Names: ALPN 101; CD28/ICOS antagonist - Alpine; ICOS/CD28 antagonist - Alpine

Latest Information Update: 24 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alpine Immune Sciences
  • Class Immunotherapies; Proteins
  • Mechanism of Action CD28 antigen inhibitors; Immunosuppressants; Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Autoimmune disorders in USA (unspecified route)
  • 18 Apr 2017 Preclinical trials in Inflammation in USA (unspecified route)
  • 18 Apr 2017 Alpine Immune Sciences plans a phase I trial for Autoimmune disorders and Inflammation in unknown countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top